A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Acronyms STRIVE
- Sponsors Abbott Laboratories; AbbVie
- 05 Nov 2020 Planned End Date changed from 6 Feb 2024 to 8 Jan 2024.
- 05 Nov 2020 Planned primary completion date changed from 6 Feb 2024 to 8 Jan 2024.
- 19 Aug 2019 Planned End Date changed from 30 Jun 2021 to 6 Feb 2024.